stoxline Quote Chart Rank Option Currency Glossary
  
Viatris Inc. (VTRS)
8.84  0.05 (0.57%)    05-16 16:00
Open: 8.8
High: 8.89
Volume: 8,919,417
  
Pre. Close: 8.79
Low: 8.735
Market Cap: 10,375(M)
Technical analysis
2025-05-16 4:44:28 PM
Short term     
Mid term     
Targets 6-month :  11.17 1-year :  13.05
Resists First :  9.56 Second :  11.17
Pivot price 8.63
Supports First :  8.11 Second :  7.21
MAs MA(5) :  8.76 MA(20) :  8.43
MA(100) :  9.86 MA(250) :  10.91
MACD MACD :  0.1 Signal :  0
%K %D K(14,3) :  45.3 D(3) :  48.6
RSI RSI(14): 56.2
52-week High :  13.55 Low :  6.84
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.
[ VTRS ] has closed below upper band by 27.4%. Bollinger Bands are 38.7% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 8.9 - 8.93 8.93 - 8.97
Low: 8.64 - 8.68 8.68 - 8.72
Close: 8.77 - 8.83 8.83 - 8.9
Company Description

Viatris Inc. operates as a healthcare company worldwide. The company operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets. It offers prescription brand drugs, generic drugs, complex generic drugs, biosimilars, and active pharmaceutical ingredients (APIs). The company offers drugs in various therapeutic areas, including noncommunicable and infectious diseases; biosimilars in the areas of oncology, immunology, endocrinology, ophthalmology, and dermatology; and APIs for antibacterial, central nervous system agents, antihistamines/antiasthmatics, cardiovascular, antivirals, antidiabetics, antifungals, and proton pump inhibitor areas, as well as support services, such as diagnostic clinics, educational seminars, and digital tools to help patients better manage their health. It provides its medicines in the form of oral solid doses, injectables, complex dosage forms, and APIs to retail and pharmacy establishments, wholesalers and distributors, payers, insurers and governments, and institutions. The company distributes its products through pharmaceutical wholesalers/distributors, pharmaceutical retailers, institutional pharmacies, mail-order and e-commerce pharmacies, and specialty pharmacies. It sells its products under the Lyrica, Lipitor, Creon, Influvac, Wixela Inhub, EpiPen auto-injector, Fraxiparine, and Yupelri; Norvasc and Viagra; AMITIZA, Lipacreon, and Effexor; and Celebrex and ARV names, as well as offers biosimilars franchises, including Fulphila, Ogivri, Hulio, and SEMGLEE. The company has collaboration and licensing agreements with Revance Therapeutics, Inc.; Momenta Pharmaceuticals, Inc.; Theravance Biopharma, Inc.; Biocon Ltd.; and Fujifilm Kyowa Kirin Biologics Co. Ltd. Viatris Inc. was founded in 1961 and is headquartered in Canonsburg, Pennsylvania.

Headline News

Sat, 17 May 2025
Securities Class Action Lawsuit Filed Against Viatris Inc. (VTRS) - Levi & Korsinsky Represents Shareholders - Stockhouse

Sat, 17 May 2025
ROSEN, REGARDED INVESTOR COUNSEL, Encourages Viatris Inc. - GlobeNewswire

Fri, 16 May 2025
VTRS Investors Have Opportunity to Lead Viatris Inc. Securities Fraud Lawsuit with the Schall Law Firm - PR Newswire

Fri, 16 May 2025
VTRS Lawsuit Alert! Class Action Lawsuit Against Viatris Inc. - TipRanks

Fri, 16 May 2025
Shareholders that lost money on Viatris Inc.(VTRS) should contact Levi & Korsinsky about pending Class Action - VTRS - WV News

Thu, 15 May 2025
Deadline Alert: Viatris Inc. (VTRS) Investors Who Lost - GlobeNewswire

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Outperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Underperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Outperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Underperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Underperform
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Drug Manufacturers - Specialty & Generic
Shares Out 1,170 (M)
Shares Float 1,170 (M)
Held by Insiders 0.5 (%)
Held by Institutions 85.9 (%)
Shares Short 48,710 (K)
Shares Short P.Month 44,820 (K)
Stock Financials
EPS -3.19
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 15.6
Profit Margin -26.5 %
Operating Margin 5.6 %
Return on Assets (ttm) 2.2 %
Return on Equity (ttm) -21.3 %
Qtrly Rev. Growth -11.2 %
Gross Profit (p.s.) 4.98
Sales Per Share 12.24
EBITDA (p.s.) 3.6
Qtrly Earnings Growth 0 %
Operating Cash Flow 2,220 (M)
Levered Free Cash Flow 6,120 (M)
Stock Valuations
PE Ratio -2.78
PEG Ratio 0
Price to Book value 0.56
Price to Sales 0.72
Price to Cash Flow 4.65
Stock Dividends
Dividend 0.11
Forward Dividend 0
Dividend Yield 1.3%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android